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Abstract 
Infantile hemangioma (IH) is the most common vascular tumour of infancy. IH undergoes a 
unique life cycle consisting of robust endothelial cell proliferation and vessel formation in 
the proliferating phase, followed by spontaneous regression in the involuting phase. Our 
laboratory has shown that IH arises from multipotential stem cells termed hemangioma stem 
cells (HemSCs). However, the phenotype of HemSCs has not been fully elucidated. Here, I 
examined HemSCs and compared these lesion-derived cells to a panel of normal 
counterparts. My results show that HemSCs share similar gene expression profiles with 
human fetal liver-derived stem cells (FLSCs) and postnatal bone marrow 
mesenchymal/mesodermal progenitor cells (BM-MPCs). Specifically, all three precursor cell 
types expressed endothelial, mesenchymal, stem/progenitor, and hematopoietic lineage genes 
to varying degrees. Furthermore, for the first time, I show that proliferating IH lesions are 
immunoreactive to markers associated with hematopoiesis; namely, RUNX1, GATA2, 
GPR56, CD45 and CD150. However, HemSCs failed to produce hematopoietic colonies 
when assessed using in vitro hematopoietic activity assays. Taken together, my studies 
suggest that HemSCs express hematopoiesis-specific markers but their ability to undergo 
hematopoiesis is suppressed. Although my findings have provided greater characterization of 
HemSCs, more studies are needed to fully understand the mechanisms that regulate HemSC 
differentiation paths, and ultimately IH pathogenesis.  
 
Keywords: infantile hemangioma, hemangioma stem cells, fetal liver stem cells, bone 
marrow progenitor cells, hematopoiesis, endothelial-to-hematopoietic transition 
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Chapter 1  
1 INTRODUCTION 
1.1 Infantile hemangioma 
Infantile hemangioma (IH) is the most common vascular tumour of infancy, affecting 
approximately 5-10% of newborns each year.1-3 Although the mechanisms underlying the 
pathophysiology of IH are currently unknown, there is a higher incidence rate associated 
with infants that are female, Caucasian, born prematurely and with a low birth weight.4-8 
The majority of IH lesions are found in the head and neck regions, followed by the trunk 
and extremities.9  
IHs are assessed clinically based on how deep they reside in the dermis or subcutaneous 
tissue (as in, superficial, deep or combined), as well as their anatomical distribution.10,11 
The majority of IHs are localized, arising from a single focal point. Segmental IHs are 
distributed throughout a larger area. Lesions that are neither completely localized nor 
segmental are called indeterminate, and those that appear in multiple anatomic regions 
are known as multifocal.12,13 Based on their anatomical location, multifocal IHs can be 
indicative of complications associated with other parts of the body. For example, large, 
segmental, facial IHs can be an indication of PHACES syndrome (Posterior fossa-
hemangiomas–arterial lesions/anomalies–cardiac defects–eye abnormalities–sternal cleft 
and supraumbilical raphe syndrome).14 Additionally, the presence of multiple cutaneous 
lesions can be indicative of hepatic IH,15 which is the most common site of visceral IHs.16 
Despite the benign nature of IH, lesions can arise in areas that can cause functional 
impairment, such as in the lip or nose, or life-threatening complications, such as in the 
liver and trachea.13,15  
Usually, no signs of IH are present at birth. Rather, lesions appear weeks to months 
postnatally within the first year of life17 and then progress through a unique life cycle 
consisting of three phases: proliferation, involution, and then the involuted phase (Figure 
1.1). In the first phase, endothelial cells (ECs) rapidly proliferate to form an immature 
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vascular network.13,18 Histologically, ECs appear enlarged and are surrounded by plump 
pericytes, and cellular proliferation markers are prominent.13 IHs will typically remain in 
this phase for up to 1 year, after which ECs will show a flattened morphology and vessels 
will attain a more mature appearance, thus entering the involuting phase. During this 
time, apoptosis offsets cellular proliferation and contributes to IH regression.19 This 
period will persist for 3 to 5 years before entering the involuted phase, in which blood 
vessels are replaced by fibroadipose tissue.20 Most tumours almost completely regress by 
8 years of age, leaving a fibrofatty residuum or scar depending on the size and behaviour 
of the IH.15 
 
 
Figure 1.1  The life cycle of IH. 
Schematic diagram depicting the three stages of IH. The proliferating phase begins within 
the first few weeks after birth and is characterized by rapidly-proliferating ECs and 
recruitment of pericytes. Newly-formed blood vessels are disorganized and immature, 
until pericytes and basal membrane components stabilize the vasculature. After about one 
year, the IH lesion begins to involute. Cellularity diminishes through apoptosis, and 
remaining cells commence differentiation into adipocytes. By 8 years of age, most, if not 
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all, of the vasculature is replaced by fibrofatty tissue. EC = endothelial cell; PER = 
pericyte; BMC = basement membrane component; AD = apoptotic debris; FIB = fibrous 
tissue; ADIP = adipocyte 
 
1.1.1 Diagnosis and treatment of IHs 
Vascular ‘birthmarks’ are commonly encountered in children and are classified as IHs or 
vascular malformations. In contrast to IHs, vascular malformations are not neoplasms but 
rather, permanent developmental abnormalities of capillaries, veins, arteries or lymphatic 
vessels. The most commonly used diagnostic/confirmation tool for IH is endothelial 
glucose transporter-1 (GLUT1) immunohistochemical staining. GLUT1 is an 
erythrocyte-type transporter that is expressed by hemangioma endothelium in all three 
phases of IH development. Normally, endothelial GLUT1 expression is restricted to 
microvessels in placenta as well as those with blood-tissue barrier function. For this 
reason, GLUT1 staining has become the gold standard for IH diagnosis.21  
Given the unique ability of IH lesions to regress on their own, practitioners will often 
leave lesions untreated, though the size and nature of the lesion does not predict its 
outcome. Up to 20% of IHs result in complications such as ulceration or functional 
impairment (both of which are potentially life-threatening), or permanent 
disfigurement.22 Furthermore, 40-80% of cases will leave a permanent residual mark.23,24 
Faint traces of vasculature may be present if vessels did not regress completely, and 
ulcerated lesions tend to leave discoloration or scars.25,26 For these reasons, early 
therapeutic intervention is recommended to reduce pain, prevent complications from 
developing and to avoid potential psychosocial effects. 
Currently, the first-line therapy for treating IH lesions is propranolol, a ß-adrenergic 
receptor blocker. Discovered serendipitously for its antiproliferative effects on IH,27 it 
has been shown to be clinically superior compared to other therapeutic options in terms 
of resolution rate and reports of adverse effects.28,29 Although the definite mechanism of 
action of propranolol in IH regression is not known, it has been suggested to involve 
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vasoconstriction, inhibition of angiogenesis, as well as induction of apoptosis.30 When 
treated with propranolol, patients experience a visible colour change in their IHs within 
1-3 days. This is due to inhibition of the ß1- and ß2-adrenergic receptors found on ECs, 
which results in vessel constriction and subsequently reduced blood flow to IH lesions.27 
Propranolol also suppresses production of proangiogenic factors implicated in 
proliferating IHs, such as vascular endothelial growth factor-A (VEGF-A) and matrix 
metalloproteinases (MMPs) 2 and 9.31 These effects and the fact that it acts on many cell 
types that comprise IH (specifically ECs, stem cells, and pericytes) has resulted in a 
decrease in the use of other treatments and dampened efforts to discover new options. 
However, in rare cases where propranolol does not reduce the IH lesion and/or serious 
adverse effects are observed, alternative therapies may be considered. Currently, these 
alternative therapies include corticosteroids, topical ß-blockers and pulsed dye laser 
therapy.32-34 Occasionally, surgery will be used if the patient does not respond to 
pharmacotherapy. Other indications for surgical excision include obstruction caused by 
the lesion, deformation, bleeding or ulceration, lack of response to medical or laser 
therapy and redundant residual tissue left after IH involution.22,25 Since these treatments 
present a much higher likelihood of producing adverse effects in comparison to 
propranolol however, they are no longer recommended as a standard for managing IH.22 
 
1.1.2 Cellular components of IHs 
IHs are predominantly composed of ECs surrounded by perivascular cells known as 
pericytes. As the IH progresses through its three characteristic phases, organization of the 
IH endothelium changes dramatically. During this time, various endothelial cell surface 
markers such as CD31, CD34, CD146, vascular endothelial growth factor receptor 2 
(VEGFR2), vascular endothelial-cadherin (VE-CADH), and von Willebrand factor 
(vWF) are highly expressed.20,21 In addition, studies have shown that ECs derived from 
proliferating IHs exhibit increased proliferation and migration in vitro.23,25,26 This altered 
behavior has led to the speculation that IH arises from clonal expansion of a single 
endothelial precursor cell, referred to as an endothelial progenitor cell (EPC, now called 
endothelial colony forming cell (ECFC)), harbouring a somatic mutation.35 Indeed, a 
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study by Yu and colleagues in 2004 found that 0.1 to 2% of ECs derived from IH samples 
co-expressed endothelial cell markers (CD34 and VEGFR2) and the stem cell antigen 
CD133, supporting the existence of EPCs in IH.36  
Pericytes are elongated cells that surround ECs in microvessels including IH blood 
vessels.37 Though well-known for their role in vessel stabilization and hemodynamic 
processes,38 their involvement in IH remains obscure. Pericytes derived from 
proliferating IH lesions (termed HemPER from hereon) can be identified based on their 
expression of alpha smooth muscle actin (α-SMA),39 the pericyte marker nerve/glial 
antigen-2 (NG2),40-42 platelet-derived growth factor receptor-β (PDGFRβ),43 
calponin,20,42 and NOTCH3.44 In normal tissue, pericytes modulate EC proliferation, 
vessel maturation and vasoconstriction.38,45 However, a study that isolated pericytes from 
proliferating and involuting phase IH found that, when co-cultured with normal cord 
blood-derived ECFCs, HemPERs induced ECFC proliferation and migration.41 Even 
though this study utilized cord blood-derived ECFCs and not mature vessel-derived ECs, 
inclusion of retinal pericytes as control confirmed that HemPERs possess a pro-
angiogenic phenotype. Furthermore, contractile ability by HemPERs was suppressed, 
which may explain the high-flow characteristics of IH. This suggests that pericytes may 
have a proangiogenic role in hemangiogenesis, due to their inability to regulate vessel 
maturation.  
A significant number of mast cells have also been reported in IHs, but observations have 
been inconsistent in terms of when in IH development they are most abundant. Glowacki 
and Mulliken (1982) found the greatest mast cell numbers in proliferating lesions,46 
whereas others have reported highest counts during involution coinciding with EC 
apoptosis and capillary dropout.47-49 The current literature has not yet elucidated an exact 
role for mast cells in hemangiogenesis; however, a growing body of evidence suggests 
that they are involved in IH regression. Mast cells release various interferons and 
transforming growth factors such as interferon (IFN)-, IFN-, IFN-, and transforming 
growth factor-β (TGF-), that are known to suppress IH proliferation.50,51 Notably, 
contradicting studies also exist arguing for a proangiogenic role of mast cells, owing to 
their ability to secrete VEGF-A and fibroblast growth factor (FGF)-2.52,53 These 
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discordances in findings may perhaps imply that the roles of mast cells in IH changes 
depending on the developmental stage of the lesion. Hence further investigation is 
required to fully understand how mast cells contribute to the IH life cycle.  
Recently, multipotential stem cells have been isolated from proliferating IH lesions that 
were able to form blood vessels and IH-like lesions in vivo.54 These cells express the stem 
cell marker CD133 and undergo clonal expansion, and are thus referred to as HemSCs. 
Making up 0.2% of proliferating IHs, HemSCs have robust vessel-forming capabilities 
that have been demonstrated both in vitro and in immunodeficient mouse models. Vessels 
formed by HemSCs express characteristic IH markers GLUT1 and merosin, and naturally 
transition into adipocytes – mimicking the involuting and involuted phases of IH. The 
stem cell phenotype and plasticity of these HemSCs has been confirmed by in vivo 
studies.54 Clonally expanded (single cell) HemSCs were injected into immunodeficient 
mice. Human CD31(endothelial cell marker)-expressing cells were then isolated and 
injected into secondary immunodeficient mouse recipients. After 14 days, new blood 
vessels had formed, confirming the robust vasculogenic potential of HemSCs. Since then, 
similar results demonstrating the vessel-forming properties of HemSCs have been 
observed in other studies.55,56 Interestingly, HemSCs are also capable of differentiating 
into pericytes both in vitro and in vivo.57 In the study by Boscolo et al (2011), CD133+ 
cells were isolated from proliferating IHs, expanded, and injected into nude mice. After 7 
days, pericytes had developed around the newly-formed blood vessels, as was confirmed 
by the pericyte marker α-SMA. To confirm that these pericytes were of HemSC origin, 
GFP-labelled HemSCs were also injected. The co-expression of α-SMA and GFP 
confirmed that HemSCs give rise to pericytes. Moreover, another study showed that 
HemPER interaction with ECs was vital for proper vascular assembly in IH.41 This 
unique ability to give rise to both HemECs and HemPERs therefore emphasizes the 
principal role of HemSCs in IH pathogenesis. 
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1.1.3 Signaling pathways in IHs 
Due to the excessive development and disorganization of blood vessels characteristic of 
early phase IHs, many studies have focused on the role of VEGF-A, a universal 
proangiogenic factor, in IH. Numerous studies have confirmed that VEGF-A is the major 
growth factor responsible for HemEC proliferation.58-60 As higher VEGF-A serum 
concentrations are observed in children with proliferating IH versus involuting, this 
conclusion is not surprising.60-62 Furthermore, VEGF-A levels have been reported to drop 
following steroid treatment.60,62 
VEGF-A binds primarily to two tyrosine kinase receptors: VEGFR1/Flt-1 and 
VEGFR2/KDR. Both are found on the surface of ECs; however, they are believed to 
exert opposing effects.63 VEGFR1 is indirectly antiangiogenic, binding to VEGF-A with 
higher affinity but without transmitting a signal. In doing so, it acts as a “trap” that 
prevents VEGF-A from binding to VEGFR2, which activates downstream signals 
resulting in EC proliferation.64 However, it is the downregulation of VEGFR1 expression 
in IHs that is believed to contribute to increased VEGF-A levels and thus VEGF-A 
activity. A study found that low VEGFR1 expression resulted in increased VEGFR2 
activity due to higher VEGF-A/VEGFR2 binding.65 This reduction in VEGFR1 is due to 
downregulation of nuclear factor of activated T cells (NFAT), a transcription factor 
regulating VEGFR1 expression. More specifically, missense mutations encoding 
VEGFR2 and tumor endothelial marker-8 (TEM8) have been found in HemECs and are 
implicated in the suppression of NFAT by altering the interactions between VEGFR2, 
TEM8 and ß1-integrin, which regulate NFAT activity. This imbalance in VEGFR1 and 
VEGFR2 results in constitutive VEGFR2 signaling in HemECs, inducing EC 
proliferation and tumour development.65,66 Abnormal VEGF-A/VEGFR2 interaction may 
also be important in HemEC survival as VEGFR2 prevents ECs from undergoing 
apoptosis, whereas VEGFR1 mediates the proapoptotic effects of VEGF-A.67,68 Hence 
the imbalance of VEFR1 and VEGFR2 activity may mediate IH formation by affecting 
HemEC survival.  
Another signaling pathway involved in IH development is the NOTCH pathway, which 
orchestrates cell fate differentiation as well as angiogenesis.44,69 The NOTCH system 
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depends on juxtacrine interactions between the NOTCH receptors (NOTCH-1 to -4) and 
ligands (Delta-like (DLL)1, DLL3, DLL4, JAGGED1 and JAGGED2). A study by 
Boscolo et al (2011) showed that JAGGED1 is highly upregulated in HemECs taken 
from proliferating IHs and that this expression is required for HemSC-to-HemPER 
differentiation.57 Furthermore, silencing JAGGED1 gene expression in HemECs 
abolished HemSC-to-HemPER differentiation and reduced blood vessel formation in 
vivo. The authors proposed that IH vasculogenesis begins with differentiation of HemSCs 
into HemECs, which then promote HemSC-to-HemPER differentiation and ultimately 
vascular development. In addition, VEGF-A is known to interact with NOTCH receptors 
and ligands that promote EC survival and angiogenesis.70,71 Since high levels of VEGF-A 
are found in IH,60 this may lead to NOTCH pathway activation and induce a 
proangiogenic signaling cascade, propagating tumour development.  
Low oxygen tension (hypoxia) has been associated with tumour angiogenesis and 
neovascularization in many cancers.72-74 Though its involvement in IH is poorly defined, 
a number of studies have associated hypoxia with IH development.75,76 Clinically, a 
blanched area of skin that precedes the IH is presented at birth. Such lesions lack normal 
blood flow and may be an area of local ischemia, the causes of which are still unknown.77 
During hypoxia, the expression of transcription factor hypoxia inducible factor-1α (HIF-
1α) is upregulated in tumour cells and induces production of other proangiogenic factors, 
such as VEGF-A and stromal cell-derived factor-1α (SDF-1α).78 These factors are known 
to recruit ECFCs to ischemic areas and induce vasculogenesis.79 MMP-9 and estrogen 
also play a role in ECFC mobilization.80-82 These mediators, as well as HIF-1α, SDF-1α 
and VEGF-A, were measured in blood and tissue samples of children with proliferating 
IH and were found to be elevated.66,83 Moreover, low oxygen conditions have been 
shown to upregulate GLUT1 expression in various cell types.84,85 Thus hypoxia may 
induce ECFC localization and homing to the IH lesion, where the microenvironment 
further supports their maturation and development.86 
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1.1.4 Current theories on the origin of IH  
Various hypotheses have arisen in the past two decades regarding the origin of IH as 
investigations have been conducted. To date, it has been suggested that IH may arise 
from the placenta, from intrinsic defects or somatic mutations, or be induced by extrinsic 
factors. A unified hypothesis also exists combining both intrinsic and extrinsic theories. 
In the placenta theory, IH is believed to be caused by the embolization of placental 
precursors to the developing fetus from chorionic villus sampling (CVS) or placental 
trauma.13,87,88 Similarities in molecular marker expression as well as developmental 
timelines reinforce this notion. For example, microvessels in both placental tissue and IH 
are immunoreactive for GLUT1, Lewis Y antigen, merosin, Fc-γ receptor-IIb, 
indoleamine 2,3-deoxygenase (IDO), and type III iodothyronine deiodinase (D3).21,89 The 
placenta, like IH, undergoes a period of robust blood vessel proliferation and then 
stabilizes itself.90 Mihm Jr. and Nelson (2010) have also added a ‘metastatic niche’ 
component to this theory, in which the placenta secretes substances preparing a site (or 
‘niche’) for the homing and growth of IH precursor cells (in this case, placental 
precursors).91 However, further investigation is needed to show a conclusive role of the 
placenta in the pathogenesis of IH.   
The intrinsic theory speculates that genetic alterations in a progenitor cell are a 
contributing factor to hemangiogenesis.69 Mutations in the 5q chromosome, which 
contains genes for EC proliferation and differentiation as well as tumour suppression, 
have been associated with IH development.92 Missense mutations in VEGFR2, VEGFR3 
and TEM8 were detected in IH cells but not in cells from normal adjacent tissue.65,93 The 
progenitor origin of IH is further reinforced by nonrandom X-chromosome inactivation 
patterns exhibited in proliferating IH tissue, suggesting a monoclonal origin.94 
Additionally, elevated circulating ECFC levels have been documented in infants with IH 
and these ECFCs express GLUT1, merosin and CD32.95 In 2008, Khan et al confirmed 
the progenitor origin of IH when CD133+ multipotential stem cells isolated from 
proliferating IH tissue were able to imitate all three stages of IH when implanted into 
mice.54 The newly-formed blood vessels also expressed GLUT1 and merosin, adding 
further support to the intrinsic hypothesis of IH emergence.  
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Conversely, the extrinsic theory states that the microenvironment plays an essential role 
in inducing and regulating IH growth. Evidence shows that the epidermis overlying the 
tumour is altered in comparison to healthy, adjacent tissue.96 Levels of IFN-β, an 
antiangiogenic regulator, were significantly lower in epidermis overlying proliferative 
phase IHs compared to normal skin. Furthermore, IFN-β levels increased as the lesions 
underwent involution, with levels reaching normalcy by 5 to 11 years of age. Although 
the source responsible for this change in IFN- levels (ie. the epidermis or the IH tumour) 
was not determined, the authors suggest that the hyperplastic epidermis could very well 
play a role in disrupting angiogenic regulators in favour of IH development. Additionally,  
stromal cells in the tumour microenvironment may also influence IH growth by secreting 
VEGF41,97 and by activating alternate angiogenic pathways.98 Taken collectively, this 
evidence supports an extrinsic component in the development of IH.  
Most probably, IH development is a multi-faceted process that involves both intrinsic and 
extrinsic components. We know that IH arises from HemSCs, which are multipotential 
stem cells that are able to form GLUT1-positive blood vessels in vivo and that later 
undergo adipogenesis to produce fibrofatty residuum.54 Moreover, there is a higher 
incidence of IH in babies of mothers who underwent CVS.99 It is supposed then, that 
HemSCs may become dislodged from the placenta during CVS and home to an area in 
the developing fetus permissive to IH development, where cell-secreted growth factors 
and low oxygen levels induce HemSC differentiation and growth. 
 
1.2 Development of the circulatory system 
Insights into the origin and pathogenesis of IHs can be gained by examining the 
development of the circulatory system. In mammals, the formation of blood vessels and 
blood cells occurs in parallel through processes called vasculogenesis and hematopoiesis, 
respectively.100 Both events begin in the embryonic yolk sac (YS), where mesodermal 
cells form aggregates called blood islands. Here, the first primitive endothelial and 
hematopoietic cells emerge.101 Due to their spatiotemporal similarity, there is a long-held 
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belief that both of these cell types emerge from a common bipotential precursor cell 
known as the hemangioblast.102,103 In the YS, primitive ECs form the first vascular 
network, termed the capillary plexus,100 of which the VEGF signaling pathway is the 
primary regulator.104,105 Once the capillary plexus has formed, it begins to remodel itself 
through angiogenesis.106 This process is carefully orchestrated by many molecular 
signaling pathways such as the Tie family of receptor kinases and the TGF- 
superfamily.107 Smooth muscle cells and pericytes are also recruited in order stabilize the 
rapidly-changing endothelium,108 resulting in a highly organized network of arteries and 
veins that are structurally and functionally distinct. Through this remodeling process, 
each vascular component is able to serve a specialized purpose within the developing 
embryo.107  
Concurrent with vasculogenesis is the process of hematopoiesis, in which hematopoietic 
stem cells (HSCs) and hematopoietic progenitor cells (HPCs; distinct from HSCs with 
limited self-renewing capacity) give rise to all blood cells in the circulatory system. The 
emergence of these blood cell progenitors occurs in distinct waves and sites.109 The first 
wave, termed ‘primitive’ hematopoiesis, transpires in the YS blood islands and produces 
nucleated erythroid progenitors.109 Synchronous with the first embryonic heartbeat, it 
then quickly transitions into the second, ‘definitive’ wave. At this time, HSCs are 
produced de novo in the aorta-gonad-mesonephros region (AGM),110 umbilical 
arteries,111 and placenta;112,113 however, the AGM and placenta contribute the most to the 
HSC pool.114 Following definitive hematopoiesis, HSCs migrate to the fetal liver (FL), 
which becomes the principal hematopoietic organ for a considerable period during 
prenatal development. Shortly before birth, HSCs then home to the thymus, spleen, and 
finally the bone marrow (BM), which becomes the main source of HSCs after birth.115 
 
1.2.1 Origins of hematopoietic progenitors 
Similarities in marker expression and their synchronicity in appearance led to the 
postulation that endothelial and hematopoietic cells share a common precursor.116-119 The 
earliest studies supporting the existence of the hemangioblast arise from work in chick 
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embryos, in which mesodermal cells selected for VEGFR2 could only give rise to 
endothelial or hematopoietic colonies, but not both.120 Fetal liver kinase (FLK1, another 
term for VEGFR2), though not an exclusive marker, has been used as a means of 
potential hemangioblast isolation, as all hematopoietic and blood cells are derived from 
FLK1+ mesoderm.121,122 Disruption of the FLK1 gene in mice ablated the ability to form 
blood vessels and severely reduced hematopoietic stem and progenitor cell (HSPC) 
counts, supporting the existence of a hemangioblast-like cell.123 Whilst the hemangioblast 
concept has been proven in various animal model systems such as the mouse and 
zebrafish,102,124,125 the advent of human embryonic stem cells (hES) provided real insight 
as to whether the hemangioblast exists in humans. Work by Kennedy et al (2007) showed 
that early-stage hES cultures were able to form blast colonies with hematopoietic and 
endothelial potential.126 In addition, these hES-derived blast cells (hES-BCs) were able to 
restore vascularization in ischemic areas when injected into mice.127 Though not yet 
confirmed in hES, studies using murine-derived ES have elucidated the essential roles of 
runt-related transcription factor 1 (RUNX1), GATA binding protein 2 (GATA2), stem 
cell leukemia (SCL, typically referred to as SCL/TAL1), VEGFR2 and bone 
morphogenetic protein-4 (BMP4) transcription factors in generating hemangioblast-like 
colony forming cells.122,128-131 Depending on intrinsic and extrinsic factors, the 
hemangioblast either gives rise to an endothelial-fated progenitor cell (ECFC or 
angioblast), or a HSC.132,133 Originally, they were believed to exist only in the early 
stages of embryogenesis; however, recent evidence has emerged confirming the presence 
of hemangioblasts in the adult.134,135 This exciting finding has major implications in 
elucidating not only how the adult body repairs itself during vascular injury, but also how 
it may contribute to vascular pathologies. 
Alternatively, studies have shown an endothelial origin of HSCs. Namely, a subset of 
specialized ECs collectively known as the hemogenic endothelium (HE) gives rise to 
hematopoietic progenitors by forming intra-aortic clusters (IAC) or by budding.136 
Lineage tracing done by Zovein and colleagues (2008) revealed that, based on the 
expression of endothelial marker VE-cadherin, long-term, multilineage HSCs emerge 
from the ventral floor of the dorsal aorta of the AGM in a process known as endothelial-
to-hematopoietic transition (EHT).137 Once emerged, these HSCs migrate and seed 
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successive hematopoietic organs, where they differentiate. Indeed, multiple studies 
thereafter confirmed the AGM as a major source of HE in definitive hematopoiesis.138-140 
Currently, identification of HE has been based upon co-expression of endothelial and 
hematopoietic cell markers. Specifically, collective VE-cadherin, CD31, CD34 and CD45 
positivity has been associated with hemogenic potential and HSC emergence.109,138,141,142 
Once HSCs have disengaged from the HE or HE-associated IACs, they progressively 
lose expression of EC marker VE-cadherin and upregulate the pan-hematopoietic marker 
CD45.143,144 
Though the existence of HE has been consistently supported, the existence of a 
bipotential precursor giving rise to hematopoietic cells leaves researchers confused as to 
the true origin of HSCs. Originally, hemangioblasts were believed to exist only in the 
early stages of development, following which the HE became the main source of 
hematopoietic progenitors. Furthermore, questions remain unanswered regarding the 
origin of HE itself. Are ECs predetermined to have hemogenic potential, or do influences 
from the microenvironment instigate EHT in differentiated ECs? A middle-ground theory 
has also been proposed, in which HSCs emerge from the hemangioblast through an 
intermediate endothelial stage, the HE.144,145 However, additional evidence is required to 
support this supposition.  
 
1.2.2 Regulators of hematopoiesis 
The process of hematopoiesis and EHT is complex and involves numerous pathways and 
factors. These include the VEGF, Wnt, NOTCH and BMP pathways;146 fibroblast and 
angiopoietin growth factors;147 transcription factors (TFs) RUNX1, GATA2, and 
SCL/TAL1; and the protein G protein-coupled receptor 56 (GPR56).148-150 For my 
studies, I will focus on RUNX1, GATA2, SCL/TAL1, and GPR56. 
During embryonic development, RUNX1 has been documented to be expressed in ECs of 
definitive hematopoietic sites – that is, the AGM, YS, the placenta, and in the umbilical 
and vitelline arteries – but not in ECs elsewhere.151,152 Mice containing homozygous 
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mutations for RUNX1 show embryonic lethality at embryonic day 12.5 (E12.5) due to an 
inability of the embryo to undergo definitive FL hematopoiesis.153 Moreover, recent 
studies have shown that RUNX1 is expressed in HE located in the AGM, umbilical and 
vitelline arteries, and placenta during definitive hematopoiesis,101,154 as well as in IACs 
budding off of the HE.138 However, once HSCs have emerged from HE, RUNX1 is no 
longer required for HSC maintenance.155 Therefore RUNX1 is indispensable for HSC 
emergence, but not thereafter.  
GATA2 is another pivotal regulator of hematopoiesis. This is highlighted by the fact that 
all HSCs and most HPCs express GATA2,156 and that GATA2 knockout mice die at E10-
11 due to severe anemia.157 During hematopoiesis, GATA2 plays two functionally 
distinct roles: the production and expansion of HSCs in the AGM, and HSC proliferation 
in adult BM.158 Both loss- and gain-of-function experiments have shown that GATA2 
maintains HSC quiescence159,160 and regulates their proclivity to apoptosis161 – both of 
which are important in maintaining the HSC pool in embryonic and adult hematopoietic 
sites. It also conserves the immature state of HSPCs, as its expression decreases with 
differentiation.162 The mechanism by which GATA2 accomplishes these roles is not yet 
fully defined; however, studies suggest that it forms a multiprotein complex with TFs 
SCL/TAL1, Fli-1 proto-oncogene (FLI1), LIM domain only 2 (LMO2), RUNX1, 
lymphoblastic leukemia associated hematopoiesis regulator 1 (LYL1) and ETS 
transcription factor ERG, collectively known as the HSC “heptad” (Figure 1.2).163,164 
This heptad binds to specific coding genes and microRNA promoters, activating a 
regulatory circuit that participates in lineage differentiation during hematopoiesis and 
EHT.163-165 One of the downstream targets of the HSC heptad is GPR56. Whole 
transcriptome analysis done on mouse HSCs, hemogenic ECs, and ECs revealed that 
GPR56 is one of the most highly upregulated (38-fold) of the 530 genes investigated, 
along with the heptad TFs.166 Furthermore, in human HSC-enriched cells, all seven 
heptad TFs were found bound to the GPR56 enhancer during EHT, thus regulating its 
expression. Though the exact function of GPR56 in hematopoiesis is currently unknown, 
studies suggest that it is required for HSC generation from HE,166 for maintaining the 
HSC pool in BM,150 as well as for HSC repopulation potential in HSC engraftment.150,167 
Despite these speculations however, contradicting evidence by Rao et al (2015) showed 
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that, despite high levels of expression in murine-derived HSCs, GPR56 knockout did not 
impair HSC proliferation or survival in mice.168 Furthermore, GPR56-deficient HSCs 
were able to regenerate the hematopoietic system in BM of irradiated recipient mice to 
the same degree as wild-type HSCs. Hence the role of GPR56 in HSC development 
requires validation.   
 
 
Figure 1.2  The heptad transcription factors control fate-determination of HSCs. 
Schematic diagram illustrating the mechanism by which several TFs (RUNX1, FLI1, 
LYL1, GATA2. SCL/TAL1, LMO2, ERG) interact to form a heptad, which controls 
lineage differentiation in HSCs. 
 
No combination of markers currently exist that explicitly define HSCs. Nevertheless, 
researchers have identified surface antigens that are consistently expressed on HSCs and 
that are thus used for their potential isolation. As described previously, HSCs derived 
from hematopoietic clusters in EHT share similar cell marker expression with the 
hemogenic ECs from which they are derived. The endothelial markers VE-cadherin,169,170 
CD31,171,172 and CD34,171,173 as well as the hematopoietic markers CD45,174 
GATA2,116,175 SCL/TAL1,116 and RUNX1151 have been observed in both cell types. 
Other markers such as c-Kit109,176 and CD150177 have also been associated with HSC 
identity. However, these markers are not specific for HSCs and thus cell populations 
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isolated based on their expression are inevitably heterogeneous. Furthermore, the cell-
surface phenotype changes as HSCs develop.177 For these reasons, future studies are 
necessary in order to determine the true molecular signature of HSCs. 
 
1.3 Organs involved in vascular development 
1.3.1 The fetal liver 
The fetal liver (FL) is a well-known site of definitive hematopoiesis. At approximately 
E11-12 in the mouse,178 and day 23 and then again at day 30 in the human,179 it becomes 
the primary source of HSCs in the embryo. These hematopoietic cells are believed to be 
derived from the YS and AGM; in other words, there is little evidence that the FL 
produces HSCs de novo or participates in EHT. Instead, the FL provides a niche, which is 
a local microenvironment that maintains the HSC pool through cellular interaction and 
factor secretion.109,180 Chemoattractants such as C-X-C motif chemokine ligand 
(CXCL)12 in FL endothelium help regulate HSC homing,181,182 while cell adhesion 
markers E-selectin and vascular cell adhesion molecule 1 (VCAM-1) control their 
retention from the circulation.183 Once in the FL, ECs from the portal vessels encourage 
HSC survival and proliferation via activated protein C (APC).184 Perivascular cells 
expressing Nestin and NG2 also contribute to HSC maintenance.185 
During embryogenesis, the FL develops a complex vascular network that arises from de 
novo vessel generation and angiogenesis.186 In the early stages of development, ECs arise 
from endodermal progenitor cells.187 However, studies have also identified a cohort of 
FL-derived progenitor cells that express ECFC markers and are able to form endothelial 
colonies in vitro.188,189 A study by Cherqui et al (2006) confirmed their existence when 
CD31+Sca1+ cells isolated from the FL possessed high angiogenic potential when 
transplanted into mice.190 In this study, CD31 served as a marker of ECs and Sca1 as the 
stem cell antigen. Interestingly, ECs derived from murine FL at E12 (during the 
definitive hematopoiesis time frame) have demonstrated similar robust 
neovascularization abilities in vivo.191 During liver organogenesis, the development of the 
17 
 
hepatic vascular network is regulated by VEGF, integrin interactions and extracellular 
matrix proteins.192 Hence it is evident that the FL is not only a major site of 
hematopoiesis, but also of vascular development.  
 
1.3.2 The bone marrow 
As the skeletal system develops in the embryo, blood vessels invade and provide 
circulation throughout the developing bone. In mice this occurs at E12.5193 and in human 
at about 10.5 weeks.179 This vascular intrusion allows for homing of HSCs from the FL, 
and from hereon the BM becomes the primary source of HSCs postnatally. However, 
unlike FL-HSCs which are highly proliferative, those in the BM are largely quiescent.194 
This is to maintain an appropriate number of differentiated blood cells in the adult and 
renew HSCs on an as-needed basis.  
In the BM, HSCs localize to sinusoids, where they interact with various cell types that 
regulate their quiescence and differentiation state.185,195 These include osteoblasts,196,197 
perivascular cells,198 ECs,199 mesenchymal stem cells (MSCs),200 adipocytes,201 and 
neurons of the sympathetic nervous system.202 Many of these cells express stem cell 
factor (SCF) and/or CXCL12, which are critical for HSC maintenance.198,203,204 In 
addition to ligand-receptor interactions, the BM houses HSCs in the endosteum, which is 
a relatively hypoxic environment.205-207 Though the mechanism by which low oxygen 
tension maintains HSC quiescence is not yet fully understood, studies suggest it could be 
by regulating factors important for hematopoiesis as well as for cell cycle progression. 
For example, hypoxia appears to upregulate expression of VEGF,208 SCF,209 and 
NOTCH1,210 all of which are involved in HSC maintenance, by oxygen-sensitive HIF-
1. HIF-1 is also important in maintaining HSCs in G0, as it upregulates cell-cycle 
inhibitors p21Cip1211 and p57kip2212. Furthermore, the low-oxygen environment appears to 
protect HSCs from reactive oxygen species (ROS).213,214 Therefore both the molecular 
and physical components of the BM make it an ideal microenvironment for adult HSCs. 
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Emerging evidence suggests that the BM is not only a source of HSCs, but also of 
ECFCs. These ECFCs can be mobilized from the BM, enter the circulation and travel to 
sites of ischemia and/or injury where they undergo neovascularization.215,216 Shi et al 
(2008) isolated cells based on CD45 expression from human BM and cultured them in 
media supplemented with basic FGF (bFGF), insulin-like growth factor-1 (IGF-1), and 
VEGF.189 They found that, after 15 to 20 days in culture, the CD45+ cells formed 
adherent EC-like colonies. Furthermore, these cells expressed vWF and incorporated 
acetylated low-density lipoprotein (LDL). The presence of ECFCs in the BM has also 
been repeatedly investigated in vivo. In these studies, cells isolated for certain endothelial 
and hematopoietic markers were implanted into animals with organ-specific ischemic 
injuries. In all cases, implanted ECFC-like cells restored the vasculature at the sites of 
injury,217-219 reaffirming a vasculogenic role of precursor cells in the BM. 
 
  
19 
 
1.3 Rationale 
Previous work done in our laboratory has shown that IH arises from multipotential stem 
cells, termed hemangioma stem cells (HemSCs).54 However, the origin of HemSCs has 
not been elucidated. During embryogenesis, blood vessels and blood cells are believed to 
develop in parallel at various sites from a common bipotential precursor cell called a 
hemangioblast.220 Based on the developmental time and the microenvironment, these 
hemangioblasts commit to becoming hematopoietic or endothelial precursors.221,222 It was 
originally believed that these hemangioblasts are present only in mesoderm and in  the 
early developing embryo (that is, the yolk sac blood islands),223 and that angioblasts and 
hemogenic endothelium give rise to endothelial and hematopoietic cells, respectively, for 
the remainder of embryonic development and in adult life.103,224 However, recent 
evidence suggests that adult hemangioblasts do in fact exist, and are able to form ECs  
both in vitro and in vivo.103,135,225-227 Given that IHs arise from HemSCs with 
vasculogenic but not hematopoietic potential, I wanted to investigate whether HemSCs 
show similarity to the hemangioblast, and if so, what mechanisms are involved in its 
endothelial versus hematopoietic commitment. By doing so, I aimed to provide novel 
insight into the origin of HemSCs and how they develop into IH. 
 
1.4 Hypothesis 
I hypothesize that IH stem cells will express markers of hematopoiesis but will be 
incapable of undergoing hematopoiesis. If true, my studies will support the idea that IH 
represents abnormal homing of a bilineage mesodermal precursor, specifically along the 
migration from fetal liver to bone-marrow (Figure 1.3).  
1.4.1 Specific Aims 
In order to test my hypothesis, I established the following two aims: 
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1. To compare the expression profile of HemSCs and normal stem/progenitor 
cells, including bone marrow-mesodermal progenitor cells (BM-MPCs) 
and fetal liver stem cells (FLSCs). 
2. To compare the differentiation potential of HemSCs, BM-MPCs, and 
FLSCs. 
 
 
Figure 1.3  Stepwise migration of the hemangioblast during embryogenesis, 
potentially giving rise to IH.  
The hemangioblast may divert from its path either from the fetal liver before birth, or 
from the bone marrow postnatally. E = embryonic day; D = day; HBL = hemangioblast; 
AGM = aorta-gonad-mesonephros region; HemSC = IH-derived stem cell; IH = infantile 
hemangioma 
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Chapter 2  
2 Materials and Methods 
2.1 IH cell culture 
CD133-selected cells from proliferating IH specimens (HemSCs) were kindly provided 
by Dr. Joyce Bischoff (Children’s Hospital Boston, Boston, MA). We have previously 
characterized these cells through RT-PCR, immunostaining, and cellular activity assays.54 
Bone marrow mesenchymal progenitor cells (BM-MPCs) were isolated from bone 
marrow mononuclear cell (BM-MNC) preparations (2M-125B, Lonza Inc., Walkersville, 
MD). For my hematopoiesis assay, fresh BM-MNCs were graciously given by Dr. David 
Hess (Western University, ON). Both BM-MPCs and BM-MNCs were used as normal 
stem/progenitor cell controls. CD133-selected human fetal liver cells (FLSCs) were 
obtained from Applied Biological Materials (Richmond, BC, Canada) and were also used 
as normal stem cell controls. All cells were cultured in complete EBM-2 media (Lonza, 
Walkersville, MD) supplemented with 20% fetal bovine serum (Lonza), EGM-2 
SingleQuots (CC-4176, Lonza Inc.) and 1X antibiotic antimycotic media (PSF; Life 
Technologies). EGM-2 SingleQuots contain epidermal growth factor, VEGF-A, IGF-1, 
bFGF, hydrocortisone, ascorbic acid, and gentamycin/amphotericin B. Hereinafter this 
media is called EBM-2/20% FBS. Media was changed every other day. Cells were 
cultured under identical conditions and kept in an incubator with 5% CO2 at 37
oC. Three 
biological replicates were used for my IH samples taken from three separate patients, 
whereas BM-MPCs and FLSCs had one biological replicate.  
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2.2  RNA isolation and RT-PCR 
RNA was isolated using the RNeasy Micro Plus Kit (Qiagen, Mississauga, ON) and 
measured using Qubit RNA Broad Range Assay in a Qubit Fluorometer (Life 
Technologies). cDNA was then synthesized using iScript cDNA Synthesis Kit (Bio-Rad 
Laboratories, Hercules, CA) in T100 Thermal Cycler (Bio-Rad). Genes associated with 
stem/pluripotent, endothelial, mesenchymal, hematopoietic and adipogenic cell lineages 
were analyzed, as were markers of EHT, using individual primers outlined below by RT-
PCR (Table 2.1). Each RT-PCR reaction (individual gene) consisted of 10 µL RT2 SYBR 
Green qPCR Mastermix (Qiagen), 2 µL primer mix (Qiagen), 1 µL cDNA, and 7 µL of 
H2O for a total reaction volume of 20 µL. All reactions were performed for 40 cycles 
following the RT2 protocol: 95°C for 10 minutes (initial denaturation and polymerase 
activation); and 60°C for 1 minute (annealing and extension). Gene expression was 
analyzed by CFX Manager Software (Bio-Rad Laboratories, Inc.) using the normalized 
(ΔΔCT) method with -actin as the housekeeping gene. Analysis via RT-PCR included 
three experimental replicates and one technical replicate per RNA sample. Melting curve 
analysis was performed to ensure specific amplification. For pluripotency genes, RNA 
from human embryonic stem cells H9 (ScienCell, Catalogue # 5825) was amplified and 
melting temperatures of amplicons were compared with HemSCs, BM-MPCs, and 
FLSCs. For mesenchymal genes, RNA from human umbilical artery smooth muscle cells 
(Lonza Inc., Catalogue # CC-2579) was amplified and melting temperatures compared. 
Lastly, for endothelial cell genes, RNA from human neonatal dermal microvascular 
endothelial cells (Lonza Inc., Catalogue # CC-2516) was used as control. 
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 Table 2.1 List of primers used for RT-PCR 
  
GENE Description Source (Catalogue #) 
   
Stem Cell and Pluripotency Phenotype 
CD133 Cluster of differentiation 133, Prominin-1 Qiagen (QT00075586) 
c-KIT Tyrosine-protein kinase Kit Qiagen (QT00080409) 
DPPA4 Developmental pluripotency associated 4 Qiagen (QT00046515) 
GDF3 Growth differentiation factor 3 Qiagen (QT00014952) 
LEFTY1 Left-right determination factor 1 Qiagen (QT00037373) 
NANOG Nanog homeobox Qiagen (QT01025850) 
OCT4/POUF5 Octomer-binding transcription factor-4 Qiagen (QT00210840) 
PODXL Podocalyxin like Qiagen (QT00005138) 
SOX2 Sex determining region Y-box 2 Qiagen (QT00237601) 
ZFP42 Zinc-finger protein-42 Qiagen (QT00051009) 
   
Endothelial Phenotype 
CD34 Hematopoietic/endothelial cell surface 
glycoprotein 
Qiagen (QT00056497) 
VEGFR2/KDR Vascular endothelial growth factor 
receptor 2 
Qiagen (QT00069818) 
CD31 Platelet endothelial cell adhesion Qiagen (QT00081172) 
VE-Cadherin Vascular endothelial-cadherin Qiagen (QT00013244) 
vWF von Willebrand factor Qiagen (QT00051975) 
   
Mesenchymal Phenotype 
NT5E/CD73 5'-nucleotidase Qiagen (QT00027279) 
ENG Endoglin Qiagen (QT00013335) 
NGFR Nerve growth factor receptor Qiagen (QT00056756) 
THY1 Thy-1 cell surface antigen Qiagen (QT00023569) 
   
Hematopoiesis & EHT Phenotype 
ALCAM Activated leukocyte adhesion molecule Qiagen (QT00026824) 
PTPRC/CD45 Protein tyrosine phosphatase receptor C Qiagen (QT00028791) 
ETV6 ETS variant 6 Qiagen (QT00074648) 
FEV FEV, ETS transcription factor Qiagen (QT00215887) 
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GATA2 GATA binding protein 2 Qiagen (QT00045381) 
GATA3 GATA binding protein 3 Qiagen (QT00095501) 
RUNX1 Runt related transcription factor Qiagen (QT00026712) 
SCL/TAL1 Stem cell protein (SCL/TAL1, T-cell 
acute lymphocytic leukemia protein 1) 
Qiagen (QT00012530) 
   
Adipogenic Phenotype 
C/EBPα CCAAT/enhancer-binding protein α Qiagen (QT00203357) 
C/EBPβ CCAAT/enhancer-binding protein β Qiagen (QT00237580) 
C/EBPδ CCAAT/enhancer-binding protein δ Qiagen (QT00224357) 
PPARγ Peroxisome proliferator activated 
receptor γ 
Qiagen (QT00029841) 
FABP4 Fatty acid binding protein 4 Qiagen (QT01667694) 
LEP Leptin Qiagen (QT00030261) 
   
Housekeeping Gene 
 β-actin Housekeeping gene, beta-actin Qiagen (QT01680476) 
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2.3  Immunofluorescent cell staining 
All cells were plated at 20,000 cells/cm2 density on 4- or 8-chambered slides for 48 hours 
prior to staining to allow for adherence. Cells were fixed with methanol and then stained 
for hematopoietic and progenitor cell markers using primary antibodies for one hour at 
room temperature, with the exception of CD45 (Table 2.2). Primary antibodies were 
diluted in phosphate-buffered saline (PBS) with 1% bovine serum albumin. Following 
primary incubation, cells were incubated with Fluorescein-conjugated secondary 
antibody (Vector Laboratories, Burlingame, CA) for one hour at room temperature. 
Slides were then counterstained and mounted with ProLong® Diamond Antifade 
Mountant with DAPI (Life Technologies). Images were taken using Olympus BX-51 
fluorescent microscope (Olympus Canada Inc., Richmond Hill, ON) and SPOT Basic 
Image Capture & SPOT Advanced Microscope Imaging Software (SPOT Imaging 
Solutions, Sterling Heights, MA). Images were acquired at the same exposure for each 
antigen. Staining intensity was measured by NIH Image J software 
(https://imagej.nih.gov/ij/). Measurements were double-normalized, first to background 
levels (areas on respective slides without cells), and then to negative control slides (no 
primary antibody).    
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Table 2.2 Primary antibodies used for immunofluorescence staining 
Antigen Host Source (Catalogue #) Dilution 
    
GATA2 Rabbit Santa Cruz (sc9008) 1:200 
GPR56 Rabbit Invitrogen (720373) 1:200 
SCL/TAL1 Mouse eBioscience (E17791-101) 1:200 
CD45 Rabbit Abcam (ab10558) 1:200 
CD150 Rabbit Abcam (ab156288) 1:200 
RUNX1 Rabbit Abcam (ab189153) 1:200 
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2.4  IH specimens and immunostaining 
All studies were conducted following approval by the Research Ethics Board at Western 
University, London, Ontario, Canada. Paraffin-embedded IH specimens were obtained 
from the Department of Pathology Tissue Archives at the London Health Sciences Centre 
(LHSC, London Ontario, Canada). The proliferating phase of IH specimens was 
confirmed through medical history and histological analysis of densely packed 
capillaries. In addition, all IH sections were immunostained with GLUT1 to confirm 
diagnosis. Tissue blocks were sectioned at 5 µm thickness. Sections were deparaffinized 
in xylene, hydrated in ethanol gradient, and subjected to antigen retrieval using 
Tris/EDTA buffer (10 mM Trizma-base, 1 mM EDTA, 0.05% Tween-20, pH 9.0) in 
2100 Retriever (Electron Microscopy Sciences, Hatfield, PA).  
 
I used two separate cases of proliferating IH for my immunostaining experiments. Slides 
were blocked with 5% horse serum for 30 minutes. Without washing, primary antibodies 
outlined in Table 2.2 were added at 1:100 dilution for 1 hour at room temperature. 
Following primary antibody incubation, fluorescein- or Alexa Fluor 488-conjugated 
secondary antibodies (Vector Laboratories, Burlington, ON) were used for detection. 
Lectin from Ulex europaeus-Atto 594 conjugate (Ulex, Sigma-Aldrich) was used to stain 
for ECs. Ulex europaeus I is a lectin specific for some alpha-L-fucose-containing 
glycocompounds which are highly expressed on ECs.228 Slides were counterstained with 
DAPI (Vector Laboratories). Images were taken using the Olympus BX-51 microscope 
(Olympus Canada Inc.).  
 
Control specimens for staining comprised of early gestation human placenta (22-25 
weeks) specimens, pyogenic granuloma specimens (highly vascular tumour commonly 
used in IH studies), and human skin specimens. Only one case for each control specimen 
was used. Negative controls for staining experiments were performed without the primary 
antibody added. 
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2.5  Differentiation assays 
To assess adipogenic differentiation potential, HemSCs, BM-MPCs and FLSCs were first 
expanded in culture. Cells were then seeded into 24-well plates at a density of 50,000 
cells/cm2 in EBM2/20% growth media. Adipocyte differentiation assays typically involve 
plating cells at sub-confluent densities. However, this assay incorporates both early 
mitotic burst and then differentiation.229 To specifically assess adipogenic differentiation 
in HemSCs and normal counterparts, I elected to plate cells at confluent densities to 
minimize the contribution of different growth kinetics. After plating and allowing cells to 
adhere for 24 hours, growth media was replaced with StemPro Adipogenesis 
Differentiation Media (Adipo media; Life Technologies) or control media, which 
consisted of Adipogenesis Basal Media supplemented with 10% FBS and 1x PSF. Both 
differentiation and control media was changed every other day. After 7 days, cells were 
stained with LipidTOX (Thermo Fisher) for the presence of lipid droplets. RNA was also 
isolated at this time to perform RT-PCR for transcription factors involved in adipogenesis 
(see Table 2.1).  
Hematopoiesis was induced in HemSCs, BM-MPCs and FLSCs using MethoCult media 
(StemCell Technologies). Optimal cell seeding density was determined by testing seeding 
densities at 10K, 25K, 50K, and 100K cells/mL of Methocult media. Cells were mixed 
with MethoCult media using a 1 mL syringe/16-gauge blunt end needle and dispensed 
into 35 mm plates in duplicate cultures. After 14 days cultures were assessed for the 
presence of blast colony-forming units (BFUs) under phase-contrast microscopy. 
 
2.6  Statistical analysis 
Most of the studies are qualitative and focused on the detection of phenotype-associated 
transcripts and antigen immunoreactivity in cells and tissues. For these studies, 
appropriate positive and negative controls were included to validate the results. Statistical 
analysis was performed on quantitative mRNA data from the differentiation assay. In this 
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case, a students’ t-test was performed to compare induction media to respective control 
media. A p value of less than 0.05 was considered significant.  
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Chapter 3  
3 Results 
3.1 Transcript profiling reveals multilineage priming of IH-
derived stem cells 
My first objective was to assess the expression of genes associated with various lineages 
in CD133-selected cultures of HemSCs. For these studies, I utilized normal BM-MPCs 
and CD133-selected FLSCs cultured under identical conditions for comparisons. First, I 
used RT-PCR to confirm the expression of stem and pluripotency genes in HemSC 
cultures from three patient samples (Hem106, Hem127, and Hem115), alongside BM-
MPCs and FLSCs. Analysis of CD133 transcripts showed undetectable levels in all cell 
types studied (Figure 3.1). This is not surprising as CD133 is readily lost as soon as cells 
adhere to culture dishes following isolation from tissues. However, both HemSCs and 
FLSCs were confirmed to be positive for CD133 mRNA following isolation (data not 
shown). My results also show that all IH cell preparations expressed genes which 
exclusively mark pluripotent cells, including the Yamanaka transcription factors OCT4, 
SOX2 and NANOG.230,231 In addition, PODXL and DPPA4 were also expressed in 
HemSCs. It was interesting to find undetectable levels of TGF-β family members GDF3 
and LEFTY1 in HemSCs, perhaps indicating some level of differentiation in cultured 
cells.  
Next, I investigated the expression of mesodermal lineage genes in HemSCs. Mesoderm 
gives rise to muscle, connective tissue, dermis and subcutaneous layer of the skin, bone 
and cartilage, endothelium of blood vessels, hematopoietic cells, as well as the kidneys 
and the adrenal cortex. I expected multiple mesodermal genes to be expressed in HemSCs 
as well as the positive controls BM-MPCs and FLSCs. I utilized the same experimental 
platform to detect transcripts of various mesodermal lineages to determine whether 
HemSCs show priming towards a specific lineage. I observed expression of most 
mesodermal markers including ALCAM, ENG, CD73/NT5E, and THY1 in HemSCs 
(Figure 3.2A). NGFR expression was inconsistent, being present in only two out of three 
IH cell preparations, and in FLSCs but not BM-MPCs. Analysis of endothelial cell genes 
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showed that HemSCs express CD31, CD34, and KDR/VEGFR2 (Figure 3.2B). CD34 
was detected in all three patient samples of HemSCs and FLSCs but not BM-MPCs, 
whereas CD31 was positive in HemSCs and BM-MPCs but not FLSCs. Only VEGFR2 
expression was similar among all cell types. However, there was no detection of fully 
mature and functional ECs, otherwise indicated by VE-CADH or vWF expression, in 
HemSCs. Previous studies from our laboratory have shown that HemSCs only acquire 
markers of fully differentiated ECs upon implantation in mice.54 This suggests that the 
signal for proper endothelial differentiation are missing in vitro and may explain the lack 
of detectable VE-cadherin and vWF transcripts.  
Given that my HemSC samples expressed genes indicating a stem cell phenotype, I 
wanted to explore the possibility that they exhibit hematopoietic and EHT-related genes. 
Interestingly, I found that ETV6, GATA2, and RUNX1 were present at similar levels 
between all cell types (Figure 3.3). GPR56 was present in all three patient samples of 
HemSCs and in FLSCs but not in BM-MPCs. Furthermore, there was no detection of 
SCL/TAL1 mRNA in any of the cell lines tested. HemSCs clearly lacked the expression 
of GATA3, which was robustly expressed in FLSCs and BM-MPCs. GATA3 has been 
shown to be expressed in long-term hematopoietic stem cells (LT-HSCs), which are 
deeply quiescent HSCs capable of reconstituting all hematopoietic cell lineages 
indefinitely in irradiated mice.232 In the study by Frelin et al (2013), GATA3 induces LT-
HSCs to exit from cell cycle quiescence and decreases their long-term reconstitution 
ability. When GATA3 was deleted however, LT-HSCs exhibited enhanced regenerative 
activity and self-renewal.232 Hence the absence of GATA3 expression in HemSCs may 
point to a mechanism underlying the self-renewing and undifferentiated nature of these 
IH-initiating cells.  
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Figure 3.1  Expression of pluripotency-associated genes in IH stem cells. 
RT-PCR analysis was done on CD133-selected cultures of HemSCs from three different 
patients (Hem106, Hem115, Hem127), BM-MPCs and FLSCs at cell passages 8-10. The 
specificity of the amplification was determined by melting curve analysis. Data is 
normalized to -actin expression. Data expressed as means. Three biological replicates 
were used for HemSCs and one biological replicate for BM-MPCs and FLSCs. The 
experiment was repeated three times using one technical replicate. The figure represents 
typical results. 
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Figure 3.2  Detection of mesenchymal- and endothelial cell-selective genes in 
HemSCs. 
RT-PCR analysis was done on CD133-selected cultures of HemSCs from three different 
patients (Hem106, Hem115, Hem127), BM-MPCs and FLSCs at cell passages 8-10. The 
specificity of the amplification was determined by melting curve analysis. Data is 
normalized to -actin expression. Data expressed as means. Three biological replicates 
were used for HemSCs and one biological replicate for BM-MPCs and FLSCs. The 
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experiment was repeated three times using one technical replicate. The figure represents 
typical results. 
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Figure 3.3  Expression of genes associated with hematopoiesis and EHT. 
RT-PCR analysis was done on CD133-selected cultures of HemSCs from three different 
patients (Hem106, Hem115, Hem127), BM-MPCs and FLSCs at cell passages 8-10. The 
specificity of the amplification was determined by melting curve analysis. Data is 
normalized to -actin expression. Data expressed as means. Three biological replicates 
were used for HemSCs and one biological replicate for BM-MPCs and FLSCs. The 
experiment was repeated three times using one technical replicate. The figure represents 
typical results. 
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3.2 IH stem cells express hematopoietic-lineage proteins 
Based on my gene expression findings, I stained HemSC, FLSC and BM-MPC for 
hematopoietic and EHT antigen expression. Current literature indicates that RUNX1, 
GATA2, GPR56, and SCL/TAL1 are master regulators of hematopoiesis,233 and CD150 
is a marker found on all HSCs.195 My results show that HemSCs are immunopositive for 
RUNX1, GPR56, and CD150 (Figure 3.4 and Figure 3.5). Consistent with my gene 
analysis study, SCL/TAL1 was absent in all cell types. RUNX1 showed nuclear 
localization and CD150 was localized to the cell plasma membrane, as expected. 
Quantification of staining intensity confirmed these findings, reaffirming RUNX1, 
GPR56 and CD150 expression but not GATA2 and SCL/TAL1 in all cells investigated 
(Figure 3.5). Surprisingly, I observed GPR56 immunopositivity in cell nuclei rather than 
membranes, which was unanticipated given that GPR56 is an adhesion receptor and thus 
contains a particularly elongated extracellular domain.234 Furthermore, GPR56 is a G 
protein–coupled receptor (GPCR) and the traditional model of GPCRs entails a cell 
membrane localization where these proteins activate heterotrimeric G proteins and their 
intracellular signaling pathways. However, it should be noted that this model is not able 
to account for GPCRs, G proteins, and their downstream effectors that are found on the 
nuclear membrane or in the nucleus. Nuclear localization of GPR56 in these stem cells 
may be a readout of increased cycling and proliferation in culture. 
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Figure 3.4  Immunofluorescence staining for markers associated with hematopoiesis 
and EHT in HemSC. 
Three IH samples (Hem106, Hem115, Hem127), FLSCs and BM-MPCs were seeded on 
glass slides and stained using primary antibodies against RUNX1, GATA2, GPR56, 
SCL/TAL1 and CD150 (green). All cells were seeded at a density of 20,00 cells/cm2 and 
cultured for 48 hours prior to staining. Experiments were carried out with cells at 
passages 8-10. Images were taken at 20x magnification. Scale bar represents 200M. 
Figure is representative of images captured at multiple fields of view.  
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Figure 3.5  Fluorescence intensity analysis of hematopoietic and EHT antigens. 
 
Immunofluroescence staining intensity of hematopoiesis- and EHT-antigens was 
measured using Image J. RUNX1, GPR56 and CD150 were expressed in all cell types 
with no discernable difference. GPR56 displaying strong immunoreactivity in all cell 
types. GATA2 and SCL/TAL1 expression was absent upon normalization to negative 
control (no primary antibody). Data expressed as mean  SD. 
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3.3 IH blood vessels express hematopoietic stem cell markers 
Previous work in our lab has shown that IH originates from HemSCs, which give rise to 
GLUT1-positive microvessels.54 Whether IH vessels express proteins associated with 
hematopoietic lineage is not currently known. However, my in vitro data showed that 
some hematopoiesis- and EHT-associated genes are expressed in HemSCs. Therefore, I 
stained proliferating IH tissues for HSC markers CD45 and CD150. Surprisingly, 
samples obtained from 2 different IH patients demonstrated CD45 and CD150 reactivity 
localized to ECs (shown in yellow; ECs stained with Ulex) (Figure 3.6). Both CD45 and 
CD150 almost exclusively marked ECs in IH specimens. Intrigued by this finding, I 
speculated whether expression of HSC markers in IH endothelium was indicative of 
EHT. Thus, I also stained for EHT markers RUNX1, GATA2, SCL/TAL1 and GPR56. I 
observed RUNX1 and GATA2 positivity in ECs lining IH vessels as well as in 
perivascular cells (Figure 3.7A, B). Both GATA2 and RUNX1 showed typical nuclear 
localization.  Furthermore, both IH samples were immunoreactive to GPR56, and 
expression was found in ECs, similar to CD45 and CD150 (Figure 3.7C). SCL/TAL1 was 
not detected in either patient samples (Figure 3.7D), confirming my cell staining and 
gene analysis findings. 
Since GLUT1, the diagnostic marker for IH, has also been shown to be expressed in 
placenta,235 I wanted to compare my IH sample findings to placental tissue (22-25 
weeks). Staining of placenta specimens showed CD45 and CD150 reactivity primarily in 
the synctiotrophoblasts (Figure 3.8). Rarely, CD150 was observed in ECs present in the 
mesenchyme. RUNX1 and GATA2 stained scattered cells in the mesenchyme but 
showed no reactivity in ECs marked by Ulex labelling. Similar results were obtained for 
GPR56 showing robust positivity in the mesenchyme.   
To bolster my findings, I also stained pyogenic granuloma tissues, which is a vascular 
lesion similar to IHs (often referred to as ‘eruptive’ or ‘lobular’ IH) and commonly used 
in IH research for comparisons. Recent molecular studies have shown that pyogenic 
granuloma exhibits high enrichment for gene ontology corresponding to vasculature 
development.236 Furthermore, ECs in pyogenic granuloma also express OCT4, SOX2, 
and NANOG.237 Therefore, I reasoned that pyogenic granuloma ECs will share the 
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expression of key hematopoietic and EHT-related proteins with IHs. As expected, I found 
antigen staining of pyogenic granuloma to parallel results obtained from IH specimens 
(Figure 3.9). CD45, CD150, and GPR56 displayed co-localization to the ECs in pyogenic 
granuloma. In addition, RUNX1 and GATA2, although expressed, did not display 
immunopositivity in the endothelium. These transcription factors were found primarily in 
the interstitium. 
For my immunostaining studies, I used human adult skin tissues as a negative control for 
hematopoietic markers. None of the hematopoietic cell markers were seen in ECs (Figure 
3.10). Although CD45 expression in human skin (both fetal and postnatal) has been 
reported in the literature,238,239 no discernable staining was seen in Ulex-marked ECs. 
RUNX1 and GATA2 showed reactivity in the epidermal layer. However, the pattern of 
staining (non-nuclear) suggested background signal rather than specific staining. In 
addition, GPR56 was found in the dermal layer, but again no reactivity was seen to co-
localize with Ulex marking.  
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Figure 3.6  ECs in IH specimens express HSC markers CD45 and CD150. 
IH sections were labeled with antibodies against (A) CD45 and (B) CD150 (green), Ulex 
for endothelial cells (red), and DAPI for nuclei (blue). Primary antibody and Ulex co-
localization is shown as yellow. Images were captured at multiple fields of view at 20x 
magnification. Scale bar represents 200M. Figure represents typical results for two 
cases of proliferating IH. 
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Figure 3.7  RUNX1, GATA2 and GPR56 expression in IH specimens. 
IH sections were labeled with antibodies against (A) RUNX1, (B) GATA2, (C) 
SCL/TAL1 and (D) GPR56 (green), Ulex for ECs (red), and DAPI for nuclei (blue). 
Primary antibody and Ulex co-localization is shown as yellow. Images were captured at 
multiple fields of view at 20x magnification. Scale bar represents 200M. Figure 
represents typical results for two cases of proliferating IH. 
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Figure 3.8  HSC and EHT immunofluorescence staining of placenta specimens. 
 
Placenta tissue (22-25 weeks) was labeled with antibodies against (A) CD45 (B) CD150 
(C) RUNX1, (D) GATA2, (E) GPR56 (green), Ulex for ECs (red), and DAPI for nuclei 
(blue). Primary antibody and Ulex co-localization is shown as yellow. Images were 
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captured at multiple fields of view at 20x magnification. Scale bar represents 200M. 
Figure represents typical results for one case of placenta tissue (22-25 weeks).  
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Figure 3.9  HSC and EHT immunofluorescence staining of pyogenic granuloma. 
 
Pyogenic granuloma samples were labeled with antibodies against (A) CD45 (B) CD150 
(C) RUNX1, (D) GATA2, (E) GPR56 (green), Ulex for ECs (red), and DAPI for nuclei 
(blue). Primary antibody and Ulex co-localization is shown as yellow. Images were 
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captured at multiple fields of view at 20x magnification. Scale bar represents 200M. 
Figure represents typical results for one case of pyogenic granuloma.  
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Figure 3.10  HSC and EHT immunofluorescence staining of human adult skin. 
 
Human adult skin samples were labeled with antibodies against (A) CD45 (B) CD150 (C) 
RUNX1, (D) GATA2, (E) GPR56 (green), Ulex for ECs (red), and DAPI for nuclei 
(blue). Primary antibody and Ulex co-localization is shown as yellow. Images were 
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captured at multiple fields of view at 20x magnification. Scale bar represents 200M. 
Figure represents typical results for one case of human adult skin.  
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3.4 IH stem cells lack hematopoietic differentiation ability in vitro 
Our laboratory has previously shown that HemSCs are able to differentiate into 
mesenchymal cells (adipocytes, osteocytes, chondrocytes) and ECs, but cannot undergo 
hematopoietic differentiation as assessed by traditional in vitro assays.54,240 Based on my 
findings that HSC and EHT markers are expressed in HemSCs and in proliferating IH 
tissues, I wanted to confirm the selective differentiation potential of HemSCs.  
First, I induced adipogenesis in HemSC cultures and analyzed for lipid droplet formation 
and adipocyte gene expression, using BM-MPCs as control. I found that HemSCs 
displayed robust lipid formation, similar to BM-MPCs, whereas FLSCs did not (Figure 
3.11). I then utilized RT-PCR to confirm adipogenic differentiation in HemSCs by 
measuring CCAAT/enhancer-binding proteins (C/EBP)-, -, and -, peroxisome 
proliferator-activated receptor gamma (PPAR), Leptin, and fatty acid binding protein 4 
(FABP4) mRNA levels. C/EBPs (, , ) and PPAR are transcriptional factors required 
for adipogenic differentiation. Once cells fully differentiate into adipocytes, late markers 
such as Leptin and FABP4 are induced. As expected from the LipidTOX staining results, 
HemSCs showed upregulation of C/EBPδ and PPARγ compared to the control/non-
inducing media. Interestingly, however, I also observed increased adipocyte marker 
expression in FLSCs. Though no studies have investigated the adipogenic potential of 
CD133-selected FLSCs, a recent study by Wang et al (2016) showed that mesenchymal 
stem cells (MSCs) isolated from fetal liver are unable to differentiate into adipocytes.241 
Hence my studies may perhaps suggest that FLSCs respond to external pro-adipogenic 
stimuli, but their ability to accumulate lipid droplets (as seen by the complete absence of 
LipidTOX positivity) is inhibited.  
I then sought to determine whether HemSCs can differentiate into hematopoietic 
lineages. We have previously shown that this may not be the case.54 However, one key 
piece of information was missing previously. My gene expression analyses showed 
variable expression of select genes which may point to differential ability of HemSCs for 
hematopoietic differentiation. For example, Hem127 expressed NGFR (Figure 3.2) but 
lacked detectable mRNA for FEV (Figure 3.3). Whereas, Hem115 lacked NGFR but 
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expressed FEV. NGFR has been shown to be expressed on non-hematopoietic stem cells 
in the marrow.242 Furthermore, FEV is designated as a key fetal hematopoiesis 
regulator.243 Therefore, I tested Hem115 and Hem127 for hematopoietic differentiation 
ability and used bone marrow-derived mononuclear cells (BM-MNCs) as my positive 
control. My results show that after 14 days of induction in Methocult media, no blast 
colony-forming units (BFUs) are produced in either HemSC cultures (Figure 3.13). 
Similarly, no hematopoietic activity was observed in FLSCs. These results suggest that in 
vitro culture of HemSCs possibly strips the cells of hematopoietic activity or that 
hematopoietic activity may be inhibited in HemSCs. 
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Figure 3.11  HemSCs are able to differentiate into adipocytes similar to BM-MPCs. 
HemSCs (Hem106), FLSCs and BM-MPCs were cultured in adipocyte induction media 
for 7 days before staining for lipid droplets with LipidTOX (green). BM-MPCs were used 
as a positive control. Cells were at passages 6-8 at the time of induction. Images were 
taken at multiple fields of view at 4x magnification. Scale bar represents 100M. Figure 
represents typical results.  
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Figure 3.12  Induction of adipogenesis-specific transcription factors in HemSCs 
upon differentiation.  
HemSCs (Hem106), FLSCs and BM-MPCs were cultured in adipocyte induction media 
and control media (basal adipogenic media without differentiation factors) for 7 days 
prior to gene analysis. Markers specific for adipocytes were assessed: (A) C/EBP, (B) 
C/EBP, (C) C/EBP, (D) PPAR, (E) Leptin, and (F) FABP4. Values represent fold-
change expression relative to control media. BM-MPCs were used as a positive control. 
Cells were at passages 6-8 at the time of induction. Data expressed as mean  SD. 
*p<0.05 compared to respective control media. 
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Figure 3.13  HemSCs are unable to form hematopoietic colonies in vitro. 
(A) Hem127, (B) Hem115, (C) FLSCs and (D) BM-MNCs were plated at a seeding 
density of 10,000 cells/mL of Methocult induction media. After 14 days, cultures were 
analyzed for the formation of blast colony-forming units (BFUs), such as seen in BM-
MNCs (D). Cells were at passages 6-8 at the time of induction, except for BM-MNCs, 
which were at passage 0. Images were taken at multiple fields of view at 4x 
magnification. Scale bar represents 100M. Figure represents typical results.  
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Chapter 4  
4 Conclusions 
4.1 Discussion 
One of the key findings of my studies is the expression of hematopoiesis-related genes in 
IH-derived stem cells (HemSCs). I show that HemSCs express genes of mesenchymal, 
endothelial, and hematopoietic lineages in culture, as expected of multipotential stem 
cells. Surprisingly, my immunostaining experiments showed co-localization of CD45, 
CD150, GATA2, and RUNX1 in ECs lining IH vessels in proliferating IH tissue samples. 
However, HemSCs lack hematopoietic activity when assessed in culture. These findings 
have provided greater insight into the phenotype of IH-initiating cells and may lead to the 
discovery of the cellular origin of IHs.   
I first set out to investigate the transcript profile of HemSCs. I screened for genes 
characteristic of pluripotent stem, mesenchymal, and endothelial cells. As expected, 
HemSCs expressed NANOG, OCT4, and SOX2, which are transcription factors known to 
maintain pluripotency and have been implicated in various malignancies.244-246 In a 
seminal study, SOX2 in conjunction with OCT4, c-MYC, and KLF4 was found to be 
sufficient for producing induced pluripotent stem cells from mouse cells.247 Furthermore, 
hypermethylation of binding sites and downregulation of SOX2 and OCT4 strips 
pluripotency in germ cells.248  In my studies, I also show that HemSCs expressed the 
pluripotency markers PODXL and DPPA4, which reaffirms their multipotential 
capabilities.  
Despite being selected for CD133, relative expression of this gene was undetectable in all 
cell types. However, previous studies have reported that CD133+ progenitor cells no 
longer express CD133 antigens once they adhere in culture.249-251 I also found that 
HemSCs expressed markers typically associated with mesenchymal stem cells (MSCs). 
Given the ability of IH-derived cells to differentiate into adipocytes during the involuting 
phase, this finding is not surprising. When cultured with respective induction media, 
HemSCs demonstrate the ability to differentiate into all mesenchymal cell types; namely, 
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adipocytes, chondrocytes, and osteocytes.54 Indeed, my adipogenic differentiation studies 
showed that HemSCs formed lipid droplets after several days in induction media, and 
expressed transcription factors essential for adipogenic differentiation.252    
Interestingly, despite possessing a stem cell phenotype, HemSCs expressed endothelial 
genes including CD34, VEGFR2/KDR and CD31. This may be indicative of EC priming 
in HemSCs, as reinforced by their ability to generate blood vessels in vivo.54 As co-
expression of stem and endothelial markers has been exhibited in cells undergoing EHT, I 
wanted to explore this further by detecting the expression of genes associated with 
hematopoiesis. My RT-PCR data indicates that HemSCs express some factors of EHT. 
Namely, ETV6, RUNX1, GATA2, and GPR56 were consistently expressed in all three 
HemSC cultures derived from separate patients. The presence of hematopoietic factors 
was further reinforced by my cell staining experiments in which HemSCs showed 
immunopositivity for RUNX1, GPR56 and CD150. Collectively, this suggests that 
HemSCs express markers characteristic of hematopoietic lineages in vitro. 
I then sought to determine whether my findings in culture paralleled those in IH tissue. I 
discovered that cells in proliferating IH samples express markers of HSCs. Being 
transcription factors, RUNX1 and GATA2 showed nuclear localization in IH specimens 
marking both vessel-lining ECs and interstitial cells. However, GPR56, CD45 and 
CD150 exclusively co-localized with IH endothelium. As CD45 is a well-established, 
HSC-specific marker, my findings could suggest that HemECs are undergoing an EHT-
like mechanism or at a minimum, have the signaling machinery intact. Moreover, the co-
expression of CD45 and CD150 implies a mature HSC phenotype.177 The likely event 
taking place here is that ECs lining IH vessels have an atypical, immature, and stem cell-
like phenotype. There also is the possibility that ECs in IHs are dedifferentiating in an 
EHT-like manner. The ability of ECs to transition into another cell type is reminiscent of 
endothelial-to-mesenchymal transition (EndMT) seen in cancer,253-255 and numerous 
studies have reported the interconversion of non-cancer cells into cancer stem cells 
(CSCs).256-258 This switch can be due to genetic manipulation,246 changes in the tumour 
microenvironment,257 hypoxia,259 or upon therapeutic stress, such as pharmacological 
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therapy.260 Considering that hypoxia and CVS have been linked to IH,88 these extrinsic 
factors may induce cell-fate changes in IH cells. 
The co-expression of HSC markers in IH endothelium has never been shown before; 
however, the lack of hematopoietic potential in these HemSCs demands further 
exploration. Despite expressing markers of mature HSCs and EHT, my studies show that 
HemSCs are unable to form BFUs in hematopoietic induction media. There are two 
possible explanations. First, in vitro culture of cells may have affected them. This could 
be in the form of ageing, differentiation, or lack of signals which are normally 
experienced in vivo. The fate of HSCs is known to be regulated by cytokines, adhesion 
molecules, and interaction with stromal cells in their respective niches.147,185,261 For 
example, IFN- and TNF- have been shown to inhibit hematopoiesis in vitro.262 
Additionally, activation of NOTCH1 inhibits HSC differentiation into granulocytes and 
erythrocytes by stimulating GATA2 activity.263 Hence modulation of these pathways and 
many others may explain the lack of hematopoietic activity observed in IH-derived cells. 
The second possibility, of course, is that hematopoietic activity in HemSCs may be 
inhibited (ie. these cells are primed to differentiate into ECs and adipocytes but not 
hematopoietic cells). As our knowledge of which pathways regulate hemangiogenesis is 
still very limited, I believe that future studies investigating changes in the IH 
microenvironment as it progresses through each stage will be of great significance.  One 
avenue to pursue is to examine the role of GATA3. GATA3 was expressed in both 
FLSCs and BM-MPCs but not in any of the IH cell preparations. GATA3 is a zinc-finger 
transcription factor that is essential for differentiation and function throughout the 
hematopoietic cell hierarchy and is shown to be expressed by LT-HSCs.264-266 Increased 
GATA3 expression was also associated with acquisition of a HSC gene signature in a 
lymphoblastic leukemia cell line.267 It would be interesting to determine whether 
hematopoietic activity can be unmasked in HemSCs upon induced expression of GATA3.  
Though much of my work suggests an atypical precursor-like phenotype of ECs in IHs, 
alternatively, one can speculate that HemSCs expressing HSC markers may be homing to 
vessels of the developing IH, where interaction with cells and secreted factors propels the 
HemSCs to endothelial commitment.78,268 Prior studies done in both our laboratory and in 
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others have repeatedly demonstrated the robust vasculogenic power of HemSCs in 
vivo.54,269,270 High-throughput phenotypic and genotypic analyses also indicate that 
HemSCs highly express markers for vasculogenesis and angiogenesis.98 Given that 
stem/progenitor cell trafficking is mediated by hypoxia and hypoxia-induced factors are 
upregulated in proliferating IH, it is not unlikely that the developing IH 
microenvironment is hypoxic and thus attracts circulating HemSCs.83,271 Once localized, 
nearby cells may promote endothelial differentiation. Vitiani et al (2010) have shown this 
effect in glioblastoma stem-like cells (GSCs).272 In their study, 20-90% of ECs in 
glioblastoma had identical gene expression profiles as tumour cells, suggesting that most 
of the tumour endothelium was of stem cell origin. Furthermore, injection of GSCs into 
immunodeficient mice produced glioblastomas, which is reminiscent of the study done by 
Khan et al (2008).54 The ability of stem cells to differentiate into ECs and form vascular 
networks has been described for neural stem cells,273 melanoma,274 breast cancer275 and 
prostate cancer,276 and has been coined the term ‘vasculogenic mimicry’.274 In addition, 
one study showed that melanoma cells challenged to an ischemic microenvironment in 
vivo were able to transdifferentiate into ECs and revascularize the ischemic area.277 
Hence, HemSCs may possibly exhibit transendothelial capabilities. 
The emergence of these results then begs the question: which came first, the HemSC or 
the HemEC? Did HemSCs with hematopoietic potential migrate to a site propitious to EC 
differentiation, or do changes in the microenvironment after vasculogenesis (due to 
stress, inherent mutations and/or paracrine factors) induce HemECs to differentiate into 
HemSCs, in a process reminiscent to EHT? The complexity of this question is 
exacerbated by the fact that many pathways and factors involved in EHT and HSC 
emergence, such as VEGF, hypoxia, Wnt and NOTCH, are also heavily implicated in EC 
differentiation.100,278-283 This suggests that these pathways are inherently plastic, behaving 
accordingly to external signals from the microenvironment. Perhaps then, HemSCs may 
give rise to a population of hemogenic ECs that later, under the right conditions, are able 
to revert to a stem cell-like phenotype in order to help propagate the growth of the 
developing IH. Regardless of whether this insight bears any truth, it is clear that there is 
still much to learn regarding the origin of IH and how it develops. My studies show that 
IH is a complex and dynamic disease, potentially involving mechanisms that have never 
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been considered before. Understanding the effects of various pathways, the IH 
microenvironment, and cell plasticity will not only have implications in IH management, 
but also in prevention, perhaps by manipulating forces involved in HemSC emergence 
and therefore IH development. 
 
4.2 Limitations 
All studies have limitations. In my cell culture experiments, CD133 selection was used to 
isolate putative stem cells from IHs and FL. My RT-PCR experiments revealed that 
CD133 mRNA was absent in all cell types, even those that were purified based on CD133 
expression. Although the loss of CD133 expression once CD133+ cells have adhered in 
culture has been published in the literature,249-251 cells utilized in my experiments were of 
higher passage number (6 to 10), and thus may not demonstrate true stem or progenitor 
behaviour. Furthermore, CD133-selected BM cells were not used. CD133-selected cells 
from human BM samples were cultured but did not yield sufficient cell numbers required 
to perform all gene expression and staining experiments. This may be due to the fact that 
most CD133-expressing cells in the adult marrow are HSCs which do not adhere to tissue 
culture plastic. In addition, my FLSC and BM-MPC cultures did not contain an 
appropriate tissue representation in my in situ immunohistochemical analyses, due to 
limited FL and BM tissue samples. As a result, my marker expression studies comparing 
HemSCs, FLSCs and BM-MPCs was limited to gene analysis and differentiation 
potential experiments.  
Lastly, not utilizing the animal model of IH which was developed in our laboratory is a 
limitation. It would be beneficial to compare the differential expression of hematopoietic 
genes in HemSCs to the in vivo ability of cells to home to the marrow, produce IH 
lesions, and determine whether this correlates to the involutive process in IH.  
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4.3 Future Directions 
The discovery of hematopoietic marker expression in HemSCs provides novel insight as 
to the potential mechanisms at play in IH pathogenesis. Given that IHs are vascular 
lesions and that HemSCs can differentiate into endothelial but not hematopoietic cells, it 
would be valuable to investigate the process by which hematopoiesis is suppressed in 
HemSCs. Future studies can be divided into two series: studies which immediately build 
on the findings of my study, and studies which provide a more broader perspective. 
Studies that should immediately build on the results presented here include determining 
whether freshly isolated and purified HemSCs exhibit hematopoietic activity. This study 
will address the concern of prolonged in vitro culture of IH cells. Next, I propose that 
knockdown experiments be utilized for genes involved in EHT. As I have shown above, 
certain markers of EHT are expressed in HemSCs and proliferating IH tissue. Using RNA 
interference or CRISPR/Cas9-mediated gene knockout, the effects of depleting RUNX1, 
GATA2, and GPR56 on HemSC growth and differentiation can be elucidated.  
The strong immunopositivity exhibited by GPR56 demands further investigation into its 
role in hematopoiesis and EHT. Although numerous reports state that GPR56 is an 
essential regulator of HSC generation, a recent study by Rao et al (2015) shows that it is 
actually dispensable for the development and maintenance of HSCs.168 Therefore more 
studies are needed in order to elucidate the role of GPR56 in hematopoiesis and 
ultimately IH. 
Other studies which highlight a broader perspective and bring together other discoveries 
in our laboratory include examining the role of T-box transcription factor 2 (TBX2) in 
hematopoiesis. Our laboratory has shown that knockdown of TBX2 upregulates 
expression of hematopoietic marker CD45 and downregulates endothelial marker 
CD34,240 which is reminiscent of EHT. Furthermore, TBX2 overexpression enhanced 
adipogenesis in HemSCs.284 Future studies may explore the relationship between TBX2 
and hematopoiesis by looking at TBX2 and EHT marker co-expression in involuting and 
involuted IH specimens.  
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Another pathway that is involved in IH and that has also been heavily implicated in EHT 
is the NOTCH signaling pathway. NOTCH plays an important role in vascular 
development and tumour angiogenesis.70,285-287 Both proliferating and involuting IHs 
have been shown to express NOTCH1, NOTCH3, NOTCH4, and its ligands JAGGED1 
and DLL4.288,289 Furthermore, NOTCH expression changes based on the stage of IH as 
well as cell type. A study by Wu et al (2010) reported NOTCH3 upregulation in 
HemSCs, while HemECs expressed NOTCH1 and NOTCH4.288 Notably, NOTCH1 plays 
a pivotal role in HSC emergence and self-renewal,290,291 and mediates endothelial and 
hematopoietic lineage specification in mesodermal progenitor cells.280 One of the major 
regulators of NOTCH signaling is the VEGF pathway, which is a well-established 
mediator of IH pathogenesis.292 Based on this data, I anticipate that altering NOTCH 
signaling in HemSCs may have significant implications on their ability to differentiate 
into various cell lineages, especially hematopoietic.  
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